Table 1.
Patient and treatment characteristics.
| Variable | Number of patients (%) |
|---|---|
| Age, median (range) | 70 (48–90) |
| Gender | |
| Male | 37 (79%) |
| Female | 10 (21%) |
| Cause of underlying chronic liver disease | |
| Alcohol | 22 (47%) |
| Hepatitis B | 13 (28%) |
| Hepatitis C | 22 (47%) |
| Non-alcoholic steatohepatitis | 2 (4%) |
| Child Pugh score | |
| A5 | 27 (57%) |
| A6 | 11 (24%) |
| B7 | 9 (19%) |
| ALBI grade | |
| 1 | 20 (43%) |
| 2 | 24 (51%) |
| 3 | 3 (6%) |
| HCC thrombus | |
| Absent | 21 (45%) |
| Present | 26 (55%) |
| Previous treatment | |
| Any | 23 (49%) |
| None | 24 (51%) |
| In-field tumor response at 3 months | |
| Stable disease | 21 (57%) |
| Partial response | 15 (41%) |
| Complete response | 1 (2%) |
| Baseline laboratory values, median (range) | |
| Bilirubin, μmol/L | 14 (6–42) |
| Albumin, g/L | 38 (23–47) |
| Platelet, ×109/L | 117 (55-366) |
| Gross tumor volume, mL, median (range) | 96.8 (1.3–1385.1) |
| Prescription dose, Gy, median (range) | 33 (30–54) |
| Liver mean dose, Gy, median (range) | 15.3 (4.3–18.2) |
| D800cc, Gy, median (range) | 7.4 (0–25.3) |
| Veff, %, median (range) | 39 (9–60) |
| Liver volume, mL, median (range) | 1231.4 (750–3080.7) |